Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of risk for graft-versus-host disease in children who receive less than the full doses of mini-dose methotrexate for graft-versus-host disease prophylaxis in allogeneic hematopoietic stem cell transplantation

  • Yum, Sook Kyung (Department of Pediatrics, The Catholic University of Korea College of Medicine) ;
  • Choi, Hye-Yoon (Department of Pediatrics, The Catholic University of Korea College of Medicine) ;
  • Lee, Jae Wook (Department of Pediatrics, The Catholic University of Korea College of Medicine) ;
  • Jang, Pil-Sang (Department of Pediatrics, The Catholic University of Korea College of Medicine) ;
  • Chung, Nack-Gyun (Department of Pediatrics, The Catholic University of Korea College of Medicine) ;
  • Jeong, Dae-Chul (Department of Pediatrics, The Catholic University of Korea College of Medicine) ;
  • Cho, Bin (Department of Pediatrics, The Catholic University of Korea College of Medicine) ;
  • Kim, Hack-Ki (Department of Pediatrics, The Catholic University of Korea College of Medicine)
  • 투고 : 2013.09.02
  • 심사 : 2013.10.08
  • 발행 : 2013.11.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: The use of cyclosporine and mini-dose methotrexate (MTX) is a common strategy for graftversus- host disease (GVHD) prophylaxis in allogeneic transplants. We investigated whether patients who receive fewer than the planned MTX doses are at increased risk for GVHD. Methods: The study cohort included 103 patients who received allogeneic transplants at the Department of Pediatrics of The Catholic University of Korea College of Medicine, from January 2010 to December 2011. MTX was administered on days 1, 3, 6, and 11 after transplant at a dose of 5 $mg/m^2$ each. Within the cohort, 76 patients (74%) received all 4 doses of MTX [MTX(4) group], while 27 patients (26%) received 0-3 doses [MTX(0-3) group]. Results: Although there was no difference in neutrophil engraftment between the 2 groups, platelet engraftment was significantly faster in the MTX(4) group (median, 15 days), compared to the MTX(0- 3) group (median, 25 days; P =0.034). The incidence of grades II-IV acute GVHD was not different between the MTX(4) and MTX(0-3) groups (P =0.417). In the multivariate study, human leukocyte antigen mismatch was the most significant factor causing grades II-IV acute GVHD (P =0.002), followed by female donor to male recipient transplant (P =0.034). No difference was found between the MTX(4) and MTX (0-3) groups regarding grades III-IV acute GVHD, chronic GVHD, and disease-free survival. Conclusion: Our results indicate that deviations from the full dose schedule of MTX for GVHD prophylaxis do not lead to increased incidence of either acute or chronic GVHD.

키워드

참고문헌

  1. Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza FR Jr, Ringden O, et al. Higher mortality after allogeneic peripheralblood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004;22:4872-80. https://doi.org/10.1200/JCO.2004.02.189
  2. Zecca M, Prete A, Rondelli R, Lanino E, Balduzzi A, Messina C, et al. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood 2002;100:1192-200. https://doi.org/10.1182/blood-2001-11-0059
  3. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314:729-35. https://doi.org/10.1056/NEJM198603203141201
  4. Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLAidentical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989;73:1729-34.
  5. Ringden O, Horowitz MM, Sondel P, Gale RP, Biggs JC, Champlin RE, et al. Methotrexate, cyclosporine, or both to prevent graftversus- host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 1993;81:1094-101.
  6. Iravani M, Mousavi A, Gholibeikian S, Bahar B, Samiee S, Ashouri A, et al. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation. Bone Marrow Transplant 2005;35:1095-9. https://doi.org/10.1038/sj.bmt.1704935
  7. Storb R, Sanders JE, Pepe M, Anasetti C, Appelbaum FR, Buckner CD, et al. Graft-versus-host disease prophylaxis with methotrexate/ cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts. Blood 1991;78:1144-5.
  8. Atkinson K, Downs K. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation. Bone Marrow Transplant 1995;16:755-8.
  9. Kumar S, Wolf RC, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, et al. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease. Bone Marrow Transplant 2002;30:161-5. https://doi.org/10.1038/sj.bmt.1703616
  10. Medd P, Monk I, Danby R, Malladi R, Clifford R, Ellis A, et al. Methotrexate dose delivery is more important than ciclosporin level in graft-versus-host disease prophylaxis following T-replete reduced-intensity sibling allogeneic stem cell transplant. Int J Hematol 2011;94:266-78. https://doi.org/10.1007/s12185-011-0920-x
  11. Chung NG, Lee JW, Jang PS, Jeong DC, Cho B, Kim HK. Reduced dose cyclophosphamide, fludarabine and antithymocyte globulin for sibling and unrelated transplant of children with severe and very severe aplastic anemia. Pediatr Transplant 2013;17:387-93. https://doi.org/10.1111/petr.12073
  12. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825-8.
  13. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9:215-33. https://doi.org/10.1053/bbmt.2003.50026
  14. Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 2010;45:1388-95. https://doi.org/10.1038/bmt.2009.359
  15. Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ, et al. Sirolimus and tacrolimus without methotrexate as graft-versushost disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004;10:328-36. https://doi.org/10.1016/j.bbmt.2003.12.305
  16. Gori E, Arpinati M, Bonifazi F, Errico A, Mega A, Alberani F, et al. Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. Bone Marrow Transplant 2007;39:347-52. https://doi.org/10.1038/sj.bmt.1705590
  17. Bechard LJ, Guinan EC, Feldman HA, Tang V, Duggan C. Prognostic factors in the resumption of oral dietary intake after allogeneic hematopoietic stem cell transplantation (HSCT) in children. JPEN J Parenter Enteral Nutr 2007;31:295-301. https://doi.org/10.1177/0148607107031004295
  18. Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L, et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005;11:383-8. https://doi.org/10.1016/j.bbmt.2005.02.006
  19. Lin YF, Lairson DR, Chan W, Du XL, Leung KS, Kennedy-Nasser AA, et al. Children with acute leukemia: a comparison of outcomes from allogeneic blood stem cell and bone marrow transplantation. Pediatr Blood Cancer 2011;56:143-51. https://doi.org/10.1002/pbc.22677
  20. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004;104:1923-30. https://doi.org/10.1182/blood-2004-03-0803
  21. Kondo M, Kojima S, Horibe K, Kato K, Matsuyama T. Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children. Bone Marrow Transplant 2001;27:727-30. https://doi.org/10.1038/sj.bmt.1702868
  22. Kalwak K, Porwolik J, Mielcarek M, Gorczynska E, Owoc-Lempach J, Ussowicz M, et al. Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant 2010;16:1388-401. https://doi.org/10.1016/j.bbmt.2010.04.001
  23. Meisel R, Klingebiel T, Dilloo D; German/Austrian Pediatric Registry for Stem Cell Transplantation. Peripheral blood stem cells versus bone marrow in pediatric unrelated donor stem cell transplantation. Blood 2013;121:863-5. https://doi.org/10.1182/blood-2012-12-469668
  24. Svennilson J, Remberger M, Ringden O. Risk factors for moderateto- severe acute graft-vs.-host disease after allogeneic stem cell transplantation in children. Pediatr Transplant 2003;7:130-6. https://doi.org/10.1034/j.1399-3046.2003.00030.x